Extended indication Extension of indication to include additional non-malignant transplant indications (non-malignant diseases in the paediatric population)
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Treosulfan
Domain Hematology
Reason of inclusion Indication extension IND
Main indication Stem cell transplants
Extended indication Extension of indication to include additional non-malignant transplant indications (non-malignant diseases in the paediatric population)
Proprietary name Trecondi
Manufacturer Medac
Mechanism of action Alkylating agent
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date April 2022
Expected Registration February 2023
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Frequency of administration 1 times a day
Dosage per administration 10 g/m2
References NCT02349906

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

References farmacotherapeutisch kompas
Additional remarks - Trecondi, 1.000mg poeder voor oplossing voor infusie: €135,15 - Trecondi, 5.000mg poeder voor oplossing voor infusie: € 670,33

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information